BOD to Supply for PTSD Study



BOD Australia (ASX: BDA) will be supplying its medicinal cannabis product MediCabilis to PTSD patients in a 12 month study with Cannabis Access Clinics.

This comes at a time when there is growing attention in North America for the use of medicinal cannabis to treat PTSD, specifically for veterans. People with PTSD may develop feelings of intense fear, anxiety, helplessness and horror, and it is estimated that around 12% of Australians suffer from it.

Through Cannabis Access Clinics, patients will be recruited and screened into the observational study. Patients will be monitored over a 12 month period, using BOD’s CBD product MediCabilis.

While this study will help increase understanding of medicinal cannabis’ use to treat PTSD, it will also increase product uptake for BOD, and subsequently the company’s revenue.

Bod Australia CEO Jo Patterson said, “Post Traumatic Stress Disorder is widespread and debilitating on a global scale. The Australian Defence Force has reported that an estimated 90% of members have experienced at least one potentially traumatic event at some time of their life, which may result in symptoms of PTSD.

“We look forward to progressing this trial as it has the potential to significantly strengthen our revenue stream, as well as further validate our product suite.

“BOD is continuing to progress commercialisation and export activities and the Board and management team look forward to updating shareholders on developments in the near term.”

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”